Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”

We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other stocks that Jim Cramer discusses.

When a caller inquired about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), Cramer said:

“You know, look, it doesn’t make any money. I’ve been waiting for it to do something, break out. I just don’t know if it has the horses.”

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn't Make Any Money”

A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) develops RNA-based treatments for a wide range of hard-to-treat diseases, with multiple drug candidates in clinical trials targeting conditions such as cardiovascular disorders, liver disease, pulmonary illness, and rare genetic disorders. Additionally, in 2019, Cramer said the following about the company:

“I looked at Arrowhead recently and I didn’t see that much. You know, everyone’s so excited about it. I don’t get that. I have been saying that it’s absolutely O.K. to own stocks that have to do with slicing and dicing and genes, but I’m not gonna endorse it for anything other than speculation.”

For context, since the above comment was aired, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock declined more than 75%.

Overall, ARWR ranks 12th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of ARWR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARWR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.